Penumbra, Inc.

NYSE:PEN

Medical - Devices

Healthcare
$320.60 -0.72%

-$2.30 today

Market cap
$12.64B
Beta
0.70
P/E (TTM)
72.6
EPS (TTM)
$4.36
52W Low $221.26High $362.41

Volume 0.21M

Average 0.50M

PEN Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Penumbra, Inc.NYSE: PEN

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin narrows to 10.5%

Operating margin was 10.5% in Q2 FY2026, down 1.5 pp from a year earlier. On a trailing-twelve-month basis it was 12.4%, up 0.0 pp year over year. Over 3 fiscal years it widened by 12.8 pp.

Context

  • Operating margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 6 analysts of 15.0% for the fiscal year ending Dec 2026, up from 13.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
10.5%+0.3 pp QoQ
Last fiscal yearDec 2025
13.5%+6.3 pp YoY
LTMJun 2026
12.4%+0.0 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.5 pp+1.3 pp+2.8 pp
1 year+6.3 pp+1.5 pp-4.8 pp
3 years+12.8 pp+4.2 pp-8.6 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
13.5%
Year-over-year change
+6.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How PEN compares with its peers on the latest reported figures

  • PEN's LTM Jun 2026 operating margin of 12.4% is the 8th highest of the 9 companies compared; the peer median is 19.8%.
  • Its year-over-year change of +0.0 pp is the 7th highest of 9, against a peer median of +1.7 pp.
  • Over three fiscal years its change of +12.8 pp compares with a peer median of +2.1 pp.
PEN Competitors Peer median
Operating Margin for PEN and competitors
Company Period LTM level YoY 3-year change
LMATLeMaitre Vascular, Inc.LTM Mar 202628.5% +5.1 pp+10.6 pp
ISRGIntuitive Surgical, Inc.LTM Sep 202628.4% -0.9 pp+3.9 pp
EWEdwards Lifesciences CorporationLTM Jun 202628.1% +1.9 pp-4.7 pp
BSXBoston Scientific CorporationLTM Jun 202621.5% +5.4 pp+5.4 pp
MDTMedtronic plcLTM Jul 202618.1% +0.2 pp+0.2 pp
ABTAbbott LaboratoriesLTM Sep 202615.2% -2.5 pp-1.0 pp
MMSIMerit Medical Systems, Inc.LTM Sep 202613.5% +1.5 pp+4.6 pp
PENPenumbra, Inc.LTM Jun 202612.4% +0.0 pp+12.8 pp
ANGOAngioDynamics, Inc.LTM Feb 2026-8.1% +9.1 pp-4.7 pp
Peer median (excluding PEN) 19.8%+1.7 pp+2.1 pp

Competitors are the stored peer set for PEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue747.59M847.13M1.06B1.19B1.4B
Cost of Revenue272.21M311.93M375.88M439.62M461.23M
Gross Profit475.38M535.21M682.64M755M942.44M
Gross Margin63.6%63.2%64.5%63.2%67.1%
Research & Development104.55M79.41M84.42M94.78M89.77M
Selling, General & Admin378.33M449.72M506.45M573.99M663.42M
Operating Expenses482.88M529.13M609.09M668.77M753.19M
Depreciation & Amortization16.41M24.32M27.26M23.7M17.47M
EBITDA7.84M29.96M108.65M45.99M223.91M
EBITDA Margin1.0%3.5%10.3%3.8%16.0%
Operating Income(7.5M)6.08M73.55M86.22M189.25M
Operating Margin-1.0%0.7%6.9%7.2%13.5%
Interest Income2.87M1.89M6.83M13.69M16.29M
Interest Expense1.93M1.75M1.74M1.42M1.31M
Other Income / Expenses(3M)(2.19M)6.1M(65.36M)15.88M
Income Before Tax(10.5M)3.89M79.65M20.87M205.13M
Pre-Tax Margin-1.4%0.5%7.5%1.7%14.6%
Income Tax Expense(13.13M)5.89M(11.3M)6.86M27.44M
Net Income5.28M(2M)90.95M14.01M177.69M
Net Margin0.7%-0.2%8.6%1.2%12.7%
EPS (Basic)0.14(0.05)2.370.364.57
EPS (Diluted)0.14(0.05)2.320.364.52
Weighted Avg Shares36.76M37.84M38.4M38.63M38.92M
Weighted Avg Shares (Diluted)37.88M37.84M39.22M39.27M39.29M

Penumbra, Inc.

NYSE:PEN

Intrinsic Alpha fair value

Locked

Current Price

$320.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.